Literature DB >> 8600053

Concomitant overexpression of the EGFR and erbB-2 genes in renal cell carcinoma (RCC) is correlated with dedifferentiation and metastasis.

G Stumm1, S Eberwein, S Rostock-Wolf, H Stein, S Pomer, J Schlegel, R Waldherr.   

Abstract

Gene amplification or structural alteration of different erbB genes exerts a transforming effect in a variety of human neoplasms. Overexpression of the EGF receptor is associated with tumor initiation and progression of renal cell carcinoma (RCC). However, the role of erbB-2 in these processes remains unknown. We investigated 34 renal cell carcinomas for gene amplification and expression of the EGFR and erbB-2 genes at the mRNA and protein level and their relationship to pathological and clinical parameters. No amplification of both genes has been observed. However, high expression of the EGF receptor protein and p185erbB2 was frequent in RCC and statistically significantly related to higher tumor grades. We could demonstrate a close correlation of p185erbB2 overexpression with high EGF receptor levels. Co-overexpression of both receptor types was significantly associated with metastatic disease. Our results suggest a synergistic involvement of both EGF receptor and p185erbB2 in the progression of RCC.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8600053     DOI: 10.1002/(SICI)1097-0215(19960220)69:1<17::AID-IJC4>3.0.CO;2-Z

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  25 in total

1.  MiR-514a-3p inhibits cell proliferation and epithelial-mesenchymal transition by targeting EGFR in clear cell renal cell carcinoma.

Authors:  Xinwen Ke; Xing Zeng; Xian Wei; Yuanqing Shen; Jiahua Gan; Huake Tang; Zhiquan Hu
Journal:  Am J Transl Res       Date:  2017-12-15       Impact factor: 4.060

2.  EGFR mRNA is upregulated, but somatic mutations of the gene are hardly found in renal cell carcinoma in Japanese patients.

Authors:  Toshiyuki Sakaeda; Noboru Okamura; Akinobu Gotoh; Toshiro Shirakawa; Shuji Terao; Masahi Morioka; Kenji Tokui; Hisato Tanaka; Tsutomu Nakamura; Mariko Yagi; Yoshihiro Nishimura; Mitsuhiro Yokoyama; Katsuhiko Okumura
Journal:  Pharm Res       Date:  2005-09-22       Impact factor: 4.200

3.  Secreted human glycyl-tRNA synthetase implicated in defense against ERK-activated tumorigenesis.

Authors:  Min Chul Park; Taehee Kang; Da Jin; Jung Min Han; Sang Bum Kim; Yun Jung Park; Kiwon Cho; Young Woo Park; Min Guo; Weiwei He; Xiang-Lei Yang; Paul Schimmel; Sunghoon Kim
Journal:  Proc Natl Acad Sci U S A       Date:  2012-02-15       Impact factor: 11.205

4.  Integrin alpha5/beta1 mediates fibronectin-dependent epithelial cell proliferation through epidermal growth factor receptor activation.

Authors:  S K Kuwada; X Li
Journal:  Mol Biol Cell       Date:  2000-07       Impact factor: 4.138

5.  Targeted therapy in renal cancer.

Authors:  Tanya B Dorff; Amir Goldkorn; David I Quinn
Journal:  Ther Adv Med Oncol       Date:  2009-11       Impact factor: 8.168

6.  A phase II trial of gefitinib and pegylated IFNα in previously treated renal cell carcinoma.

Authors:  Derek Shek; Jeff Longmate; David I Quinn; Kim A Margolin; Przemyslaw Twardowski; David R Gandara; Paul Frankel; Chong-Xian Pan; Primo N Lara
Journal:  Int J Clin Oncol       Date:  2011-03-23       Impact factor: 3.402

7.  Von Hippel-Lindau tumor suppressor gene loss in renal cell carcinoma promotes oncogenic epidermal growth factor receptor signaling via Akt-1 and MEK-1.

Authors:  S Justin Lee; Jean-Baptiste Lattouf; Julie Xanthopoulos; W Marston Linehan; Donald P Bottaro; James R Vasselli
Journal:  Eur Urol       Date:  2008-01-16       Impact factor: 20.096

8.  MicroRNA-27a functions as a tumor suppressor in renal cell carcinoma by targeting epidermal growth factor receptor.

Authors:  Yueyan Li; Jie Li; Xiaolei Sun; Jiacun Chen; Xiaoqing Sun; Junnian Zheng; Renfu Chen
Journal:  Oncol Lett       Date:  2016-04-26       Impact factor: 2.967

9.  EGFR kinase-dependent and kinase-independent roles in clear cell renal cell carcinoma.

Authors:  Paolo Cossu-Rocca; Maria R Muroni; Francesca Sanges; Giovanni Sotgiu; Anna Asunis; Luciana Tanca; Daniela Onnis; Giovanna Pira; Alessandra Manca; Simone Dore; Maria G Uras; Sara Ena; Maria R De Miglio
Journal:  Am J Cancer Res       Date:  2015-12-15       Impact factor: 6.166

Review 10.  Current status and perspective of antiangiogenic therapy for cancer: urinary cancer.

Authors:  Shigeru Kanda; Yasuyoshi Miyata; Hiroshi Kanetake
Journal:  Int J Clin Oncol       Date:  2006-04       Impact factor: 3.850

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.